Associated tags: Health, Drug discovery, ChromeOS, Patient, NSCLC, EGFR, Pharmaceutical industry, TKI, Lung cancer, Vaccine, Brain, Osimertinib, Cancer, Mutation, General of the branch, Conference, Safety, Recurrence
Locations: CALIFORNIA, KOREA, SOUTH KOREA, SEOUL
'JIN-A02' is a 4th generation EGFR-TKI targeting C797S mutation that causes resistance to 3rd generation EGFR-TKI (such as Osimertinib, Lazertinib), commonly used in the treatment of NSCLC.
Key Points:
- 'JIN-A02' is a 4th generation EGFR-TKI targeting C797S mutation that causes resistance to 3rd generation EGFR-TKI (such as Osimertinib, Lazertinib), commonly used in the treatment of NSCLC.
- This ongoing Phase 1 clinical study is currently in its 4th Dose Level of 100mg daily and patients have showed increasing clinical benefits with each increasing dose levels.
- The 5th Dose Level of 150mg daily is expected to begin in 3Q 2024.
- J INTS BIO confirmed the favorable safety and efficacy signals of 'JIN-A02' with clinical benefits in this poster presentation in San Diego and greater clinical impact is expected as the study progresses.
'JIN-A02' is a 4th generation EGFR-TKI targeting C797S mutation that causes resistance to 3rd generation EGFR-TKI (such as Osimertinib, Lazertinib), commonly used in the treatment of NSCLC.
Key Points:
- 'JIN-A02' is a 4th generation EGFR-TKI targeting C797S mutation that causes resistance to 3rd generation EGFR-TKI (such as Osimertinib, Lazertinib), commonly used in the treatment of NSCLC.
- This ongoing Phase 1 clinical study is currently in its 4th Dose Level of 100mg daily and patients have showed increasing clinical benefits with each increasing dose levels.
- The 5th Dose Level of 150mg daily is expected to begin in 3Q 2024.
- J INTS BIO confirmed the favorable safety and efficacy signals of 'JIN-A02' with clinical benefits in this poster presentation in San Diego and greater clinical impact is expected as the study progresses.
Retrieved on:
Monday, February 26, 2024
NSCLC,
Traffic barrier,
Severance Hospital,
EGFR,
ESMO,
ASCO,
Permeability,
Catholic University of Korea,
National Cancer Center,
Hospital,
Asan Medical Center,
AACR,
Society,
University,
Seoul National University Hospital,
Patient,
Clinical trial,
Oncology,
Mutation,
Trial of the century,
Cancer,
Pharmaceutical industry J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.
Key Points:
- J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.
- The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer".
- In August last year, J INTS BIO registered the first patient for the global Phase 1/2 clinical trial of 'JIN-A02' at Severance Hospital in Korea.
- A J INTS BIO official said, "The global clinical trial for 'JIN-A02' is progressing well and is receiving interest in the global market."
Retrieved on:
Monday, February 26, 2024
NSCLC,
Traffic barrier,
Severance Hospital,
EGFR,
ESMO,
Multimedia,
ASCO,
Permeability,
Catholic University of Korea,
National Cancer Center,
Hospital,
Asan Medical Center,
AACR,
Society,
University,
Seoul National University Hospital,
Patient,
Clinical trial,
Oncology,
Mutation,
Trial of the century,
Cancer,
Pharmaceutical industry J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.
Key Points:
- J INTS BIO will present a poster during the "Phase I Clinical Trials in Progress" session, which will be held on April 8 from 1:30 to 5:00 p.m.
- The topic of the presentation is "Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI for 3rd generation EGFR-TKI resistant patients in EGFR mutated advanced/metastatic non-small cell lung cancer".
- In August last year, J INTS BIO registered the first patient for the global Phase 1/2 clinical trial of 'JIN-A02' at Severance Hospital in Korea.
- A J INTS BIO official said, "The global clinical trial for 'JIN-A02' is progressing well and is receiving interest in the global market."
Retrieved on:
Tuesday, December 5, 2023
Safety,
ESMO,
Patient,
Osimertinib,
Pharmacokinetics,
Index,
Trial of the century,
MTD,
Infrared spectroscopy correlation table,
Mutation,
EGFR,
NSCLC,
Pharmaceutical industry,
Vaccine SEOUL, South Korea, Dec. 5, 2023 /PRNewswire/ -- J INTS BIO announced that early results of the Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' were presented at the ESMO Asia 2023 conference held in Singapore from 1st to 3rd December 2023.
Key Points:
- SEOUL, South Korea, Dec. 5, 2023 /PRNewswire/ -- J INTS BIO announced that early results of the Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' were presented at the ESMO Asia 2023 conference held in Singapore from 1st to 3rd December 2023.
- 'JIN-A02', a 4th generation EGFR-TKI, is a substance that selectively binds to C797S, a mutation that leads to resistance to 3rd generation EGFR-TKIs (Osimertinib, Lazertinib), a treatment for EGFR+ NSCLC.
- During ESMO Asia, the safety and PK results for the first two cohorts of patients recruited in Part A (Dose Escalation) of the clinical study were presented.
- According to J INTS BIO, the clinical study is progressing well and recruitment has been unexpectedly successful with no unnecessary delays between the cohorts.
Retrieved on:
Tuesday, December 5, 2023
Safety,
ESMO,
Patient,
Multimedia,
Osimertinib,
Pharmacokinetics,
Index,
Trial of the century,
MTD,
Infrared spectroscopy correlation table,
Mutation,
EGFR,
NSCLC,
Pharmaceutical industry,
Vaccine SEOUL, South Korea, Dec. 5, 2023 /PRNewswire/ -- J INTS BIO announced that early results of the Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' were presented at the ESMO Asia 2023 conference held in Singapore from 1st to 3rd December 2023.
Key Points:
- SEOUL, South Korea, Dec. 5, 2023 /PRNewswire/ -- J INTS BIO announced that early results of the Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' were presented at the ESMO Asia 2023 conference held in Singapore from 1st to 3rd December 2023.
- 'JIN-A02', a 4th generation EGFR-TKI, is a substance that selectively binds to C797S, a mutation that leads to resistance to 3rd generation EGFR-TKIs (Osimertinib, Lazertinib), a treatment for EGFR+ NSCLC.
- It has demonstrated strong efficacy in preclinical studies, and the results have already been presented at several academic conferences.
- According to J INTS BIO, the clinical study is progressing well and recruitment has been unexpectedly successful with no unnecessary delays between the cohorts.
Retrieved on:
Wednesday, September 13, 2023
AE,
Metastasis,
DLT,
Lung cancer,
Pharmacokinetics,
Mutation,
NSCLC,
Trial of the century,
Patient,
EGFR,
MTD,
Conference,
Safety,
Pharmaceutical industry,
Part JIN-A02, a 4th generation EGFR TKI, selectively and reversibly binds to EGFR mutations, in particular C797S mutation that led to resistance to Osimertinib therapy.
Key Points:
- JIN-A02, a 4th generation EGFR TKI, selectively and reversibly binds to EGFR mutations, in particular C797S mutation that led to resistance to Osimertinib therapy.
- In preclinical studies, JIN-A02 has demonstrated potent activities as monotherapy in models with EGFR mutations that are resistant to Osimertinib.
- This global phase 1/2 clinical study seeks to evaluate the safety, pharmacokinetics, and anti-tumor activity of "JIN-A02" in advanced NSCLC patients carrying EGFR mutations.
- This study is divided into three parts with dose escalation (Part A), dose exploration (Part B), and dose expansion (Part C).
Retrieved on:
Wednesday, September 13, 2023
AE,
Metastasis,
DLT,
Lung cancer,
Pharmacokinetics,
Mutation,
Multimedia,
NSCLC,
Trial of the century,
Patient,
EGFR,
MTD,
Conference,
Safety,
Pharmaceutical industry,
Part JIN-A02, a 4th generation EGFR TKI, selectively and reversibly binds to EGFR mutations, in particular C797S mutation that led to resistance to Osimertinib therapy.
Key Points:
- JIN-A02, a 4th generation EGFR TKI, selectively and reversibly binds to EGFR mutations, in particular C797S mutation that led to resistance to Osimertinib therapy.
- In preclinical studies, JIN-A02 has demonstrated potent activities as monotherapy in models with EGFR mutations that are resistant to Osimertinib.
- This global phase 1/2 clinical study seeks to evaluate the safety, pharmacokinetics, and anti-tumor activity of "JIN-A02" in advanced NSCLC patients carrying EGFR mutations.
- This study is divided into three parts with dose escalation (Part A), dose exploration (Part B), and dose expansion (Part C).
AACR,
HER2,
Hope,
TKI,
NSCLC,
Yuhan,
Lung cancer,
Corporation,
Patient,
Tyrosine kinase,
Cryptocurrency,
Pharmaceutical industry SEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for a Tyrosine Kinase Inhibitor (TKI) targeting HER2, 'JIN-A04'.
Key Points:
- SEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for a Tyrosine Kinase Inhibitor (TKI) targeting HER2, 'JIN-A04'.
- JIN-A04 is an oral TKI targeting non-small cell lung cancer carrying HER2 mutations, and there is currently no approved oral drug approved to date.
- Anna Jo, CEO of J INTS BIO, said, "JIN-A04 is expected to be a hope for NSCLC patients with 'HER2 Exon20 insertion' mutations."
- Meanwhile, Yuhan invested 1.5 million dollars in J INTS BIO in 2021 and 2022, respectively, and holds a 14.8% stake in the company.
AACR,
HER2,
Hope,
TKI,
Multimedia,
NSCLC,
Yuhan,
Lung cancer,
Corporation,
Patient,
Tyrosine kinase,
Cryptocurrency,
Pharmaceutical industry SEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for a Tyrosine Kinase Inhibitor (TKI) targeting HER2, 'JIN-A04'.
Key Points:
- SEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for a Tyrosine Kinase Inhibitor (TKI) targeting HER2, 'JIN-A04'.
- JIN-A04 is an oral TKI targeting non-small cell lung cancer carrying HER2 mutations, and there is currently no approved oral drug approved to date.
- Anna Jo, CEO of J INTS BIO, said, "JIN-A04 is expected to be a hope for NSCLC patients with 'HER2 Exon20 insertion' mutations."
- Meanwhile, Yuhan invested 1.5 million dollars in J INTS BIO in 2021 and 2022, respectively, and holds a 14.8% stake in the company.
